SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is honoring November as National Alzheimer’s Disease Awareness Month and National Family Caregivers Month to support those who provide unpaid care to family members requiring medical assistance and to raise awareness for those directly impacted by AD.
“We appreciate the determination and commitment of those who look to serve their family and friends with the best at-home medical care they possibly can,” says SDx President and CEO, Frank Amato. “With over 11 million people in the Unites States providing unpaid care for those with AD or other forms of dementias, SDx seeks to make the AD diagnostic process faster and more accessible by providing clarity through an early and accurate AD diagnosis.”
Over 80% of care for older Americans is currently being provided by family, friends and other unpaid caregivers, with nearly half of this care being for people with AD or another type of dementia.
Understanding that there are many causes of dementia, SDx developed the DISCERN™ test, the first and only autopsy-validated skin test, to provide healthcare professionals with a diagnostic tool to accurately identify AD in people suffering from dementia symptoms, even in the presence of mixed-dementia. A minimally invasive, routine 3mm skin punch biopsy, DISCERN can be administered in the clinician’s office and is paid for by Medicare.
“Alzheimer’s Awareness and National Caregivers months are important occasions to recognize the burden of AD and celebrate the caregivers dedicated to looking after those affected,” continues Amato. “Over 50% of people with AD also have other pathologies of dementia, the presence of which can complicate diagnosis with the current diagnostic pathway and may adversely impact treatment outcomes. The autopsy-validated accuracy from a simple procedure performed in a clinician’s office, combined with this positive economic modeling data, position DISCERN as a key solution to reduce the economic burden of AD across the healthcare system and inform an early and accurate diagnosis of AD, the first step in assessing patients for therapeutic intervention.
About SYNAPS Dx
SYNAPS Dx is a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD). The company offers DISCERN™, the first highly accurate, minimally invasive test supporting a clinician’s definitive diagnosis of AD versus other forms of dementia, even in people recently diagnosed with dementia. SYNAPS Dx’s laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high-complexity clinical laboratory testing. Physicians and patients seeking more information can visit https://discerntest.com/. For more information on the company, visit https://www.synapsdx.com/. Contact: firstname.lastname@example.org.
201.641.1911 x 21